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The Hippo pathway plays a pivotal role in tissue homeostasis and
tumor suppression. YAP and TAZ are downstream effectors of the
Hippo pathway, and their activities are tightly suppressed by
phosphorylation-dependent cytoplasmic retention. However, the
molecular mechanisms governing YAP/TAZ nuclear localization have
not been fully elucidated. Here, we report that Mastermind-like 1 and
2 (MAML1/2) are indispensable for YAP/TAZ nuclear localization and
transcriptional activities. Ectopic expression or depletion of MAML1/2
induces nuclear translocation or cytoplasmic retention of YAP/TAZ,
respectively. Additionally, mutation of the MAML nuclear localization
signal, as well as its YAP/TAZ interacting region, both abolish nuclear
localization and transcriptional activity of YAP/TAZ. Importantly, we
demonstrate that the level of MAML1 messenger RNA (mRNA) is
regulated by microRNA-30c (miR-30c) in a cell-density-dependent
manner. In vivo and clinical results suggest that MAML potentiates
YAP/TAZ oncogenic function and positively correlates with YAP/TAZ
activation in human cancer patients, suggesting pathological rele-
vance in the context of cancer development. Overall, our study not
only provides mechanistic insight into the regulation of YAP/TAZ sub-
cellular localization, but it also strongly suggests that the miR30c–
MAML–YAP/TAZ axis is a potential therapeutic target for developing
novel cancer treatments.
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The Hippo pathway is an evolutionarily conserved regulator oforgan size that functions by coordinating cell proliferation
and apoptosis (1–5). Diverse upstream inputs, such as cell den-
sity, mechanical stress, and soluble factors, tightly regulate the
Hippo pathway, which, in response to these extracellular signals,
controls cell proliferation and organ growth (6–9). Dysregulation
of the Hippo pathway induces massive overgrowth in diverse
organs due to uncontrolled cell proliferation (10–12). Hippo
signaling inactivation and subsequent Yes-associated protein
(YAP) activation induce rapid tumor progression in various
animal models and are strongly correlated with several types of
human cancers such as lung, breast, and liver cancer (10, 13–15).
Activation of the Hippo pathway is triggered by a core kinase cas-
sette that comprises the mammalian sterile 20-like kinases (MST1/
2), the large tumor suppressor (LATS1/2), and the scaffold protein
Salvador1 (SAV1) (16). Sequential phosphorylation and activation
of MST1/2 and LATS1/2 by upstream signals such as high cell
density result in phosphorylation-dependent cytoplasmic retention
of the transcriptional coactivator YAP and its paralogue TAZ
(transcriptional coactivator with PDZ-binding motif). This occurs
through interaction with 14-3-3, and the retained YAP/TAZ are
down-regulated by β-TrCP–mediated proteolytic degradation (6, 9,
17, 18). LATS1/2-mediated phosphorylation of YAP/TAZ can be
suppressed by low cell density or cell-proliferative conditions, both
of which induce the nuclear translocation of YAP/TAZ. Once in the
nucleus, YAP/TAZ interacts with TEA domain transcription factor
(TEAD), resulting in the activation of genes involved in cell pro-
liferation, antiapoptosis, and survival (19). Overall, the regulation of
YAP/TAZ subcellular localization by a variety of upstream regulators
is considered a critical regulatory step in the Hippo pathway (20–22).
In addition to cytoplasmic sequestration of YAP/TAZ through
interaction with 14-3-3 (23, 24), a number of studies have
reported alternative modulators of YAP/TAZ subcellular local-
ization (3). Merlin, Kibra, and Angiomotin have all been shown
to physically bind to and exclude YAP/TAZ from the nucleus
(20, 21, 25). Additionally, protein tyrosine phosphatase PTPN14
induces cell-density-dependent nuclear export of YAP, thereby
suppressing YAP oncogenic function (26, 27). This inhibitory
role of PTPN14 on YAP activity depends on a physical in-
teraction between PTPN14 and YAP1 and is independent of
PTPN14’s enzymatic activity (26). More recently, SET1A-
mediated monomethylation at the K342 residue of YAP (28),
binding of Dishevelled (a positive regulator of canonical Wnt
signaling) to phosphorylated YAP (29), and the interaction be-
tween TEAD and NES of YAP/TAZ (30) have also been shown
to be involved in the nuclear export of YAP. To date, the reg-
ulation of cytoplasmic sequestration of YAP/TAZ has been ex-
tensively studied; however, the molecular effectors as well as the
underlying mechanisms governing nuclear translocation and re-
tention of YAP/TAZ are unclear. In addition, unlike its Dro-
sophila ortholog Yorkie, a functional nuclear localization signal
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(NLS) sequence for YAP/TAZ has not been reported in mam-
mals, suggesting the existence of a potential novel molecular
mediator of YAP/TAZ nuclear localization.
Mastermind-like (MAML) was originally identified as a piv-
otal coactivator of Notch-dependent transcription, and three
distinct MAML genes (MAML1 to 3) are expressed in mammals.
In addition to Notch signaling, numerous studies have reported
that MAML promotes Wnt, Shh, and nuclear factor-κB signaling
target gene transcription by directly interacting with downstream
effectors of these pathways (31–33). Therefore, there is strong
evidence demonstrating Notch-independent functions of MAML
proteins in regulating various biological processes (34). How-
ever, despite its importance as a transcriptional coactivator in
various signaling pathways, the overall physiological relevance
of MAML in homeostasis and disease has not been well
studied.
Fig. 1. MAML1/2 promote the nuclear localization and transcriptional activities of YAP/TAZ. (A) Ectopically expressed MAML1 and YAP in HEK293 cells
colocalized in the nucleus. (Scale bars, 10 μm.) (B) Co-IP experiments showed that endogenous MAML1 interacts with YAP/TAZ. (C) The fluorescence signal
generated by proximity ligation assay demonstrates that endogenous MAML1 and YAP are closely located in the nucleus. (Scale bars, 10 μm.) (D) MAML1 and
MAML2, but not MAML3, increased YAP reporter activity in HCT116 cells. (E) Knockdown of MAML1/2 in HEK293A reduced nuclear localization of YAP. The
areas marked with white rectangles were magnified and shown in E, Right. (Scale bars, 50 μm.) (F) Knockdown of MAML1/2 in HEK293T cells reduced YAP
reporter activity. (G) Quantitative real-time PCR showed that knockdown of MAML1/2 in HeLa cells reduced mRNA levels of Hippo and Notch signaling target
genes. (H) A wound-healing assay showed that knockdown of MAML1/2 in HeLa cells reduced migration rate, which was induced by the ectopic expression of
YAP. In D and F–H, the statistical analyses represent average values from a representative experiment performed in triplicate. Error bars represent SDs of
triplicate assays. **P < 0.01. n.s., not significant. Student’s t test was used for statistical analysis.
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In this study, we identified MAML1 and MAML2, but not
MAML3, as potent effectors of the Hippo pathway by promoting
YAP/TAZ nuclear localization in a cell-density-dependent
manner. We discovered an evolutionarily conserved PPxY-interacting
motif within MAML1/2 that physically binds to the WW domain of
YAP/TAZ, promoting YAP/TAZ nuclear retention and consequent
transcriptional activity. Mutation of a putative MAMLNLS sequence
repressed YAP/TAZ activity, further demonstrating the importance
of MAML1/2 in regulating YAP/TAZ nuclear localization. Impor-
tantly, MAML protein abundance is controlled by expression of
microRNA-30c (miR-30c) in a cell-density-dependent manner. Fur-
thermore, analysis of various xenograft assays, The Cancer Genome
Fig. 2. Nuclear localization of MAML is essential for the retention of YAP/TAZ in the nucleus. (A) Schematic diagram of human MAML1. The red line indicates
a putative NLS sequence, and “KKTRR” was mutated to “AATLL” for inducing loss of NLS function. (B) MAML1-mNLS is present in the cytoplasm, and it does
not promote nuclear localization of YAP. (Scale bars, 10 μm.) (C) MAML1–mNLS did not increase YAP reporter activity in HCT116 cells when compared to wild-
type (WT) MAML1. Ctrl, control. (D, Left and Center) MAML1–mNLS did not rescue retarded HEK293 cell migration induced by MAML1/2 depletion. (D, Right)
Western blot shows normal expression of proteins. (E) Live cell imaging suggests that MAML1 retains YAP in the nucleus, which enhances YAP nuclear lo-
calization. (Scale bars, 10 μm.) In C, the statistical analysis represents average values from a representative experiment performed in triplicate. Error bars
represent SDs of triplicate assays. In D, Center, the statistical analysis represents average values of three different regions from a representative experiment.
Error bars represent SDs of values from three different regions. **P < 0.01. n.s., not significant. Student’s t test was used for statistical analysis.








Atlas (TCGA) database, and clinical specimens revealed that high
expression of MAML is associated with YAP/TAZ activation. Taken
together, our findings not only provide mechanistic insight into YAP/
TAZ nuclear localization, but they also propose the miR30c–
MAML–YAP/TAZ axis as a potential target for cancer treatment.
Results
MAML1/2 Promote Nuclear Localization and the Transcriptional
Activities of YAP/TAZ. To screen for proteins that promote nu-
clear localization of YAP/TAZ, the cellular localization of en-
hanced green fluorescent protein (EGFP)–YAP was examined
after cotransfection with various nuclear proteins. Interestingly,
ectopic expression of MAML1 clearly induced nuclear localiza-
tion of YAP, while other nuclear proteins had no effect (Fig. 1A
and SI Appendix, Fig. S1A). One exception was TEAD4, which
has been shown to form a complex with YAP/TAZ in the nucleus
(35). Ectopic expression of MAML1 and TAZ also induced
nuclear localization of TAZ (SI Appendix, Fig. S1B). Immuno-
precipitation (IP) assay revealed that both endogenous and ec-
topically expressed MAML1 were able to associate with YAP/
TAZ (Fig. 1B and SI Appendix, Fig. S1C). A proximity-ligation
assay, which can detect in situ protein interactions with high
specificity and sensitivity (36, 37), further confirmed that en-
dogenous MAML1 physically interacts with YAP in the nucleus
(Fig. 1C).
MAML was initially discovered to function as a coactivator of
Notch signaling, but several reports indicate that MAML may
also coactivate other signaling pathways (34). In mammalian cells,
there are three distinct members of MAML genes: MAML1, 2, and
3. We found that cotransfection of MAML1 and MAML2, but not
MAML3, promoted nuclear localization of EGFP–YAP (SI Ap-
pendix, Fig. S1D). Consistently, cotransfection of YAP or TAZ with
MAML1 or MAML2, but not MAML3, enhanced TEAD-dependent
reporter activity (8xGTIIC-Luc) (SI Appendix, Fig. S1 E and F).
Transfection ofMAML1 orMAML2, but notMAML3, into HCT116
cells, which express high levels of YAP, also promoted reporter activity
(Fig. 1D). In accordance with the above data, knockdown of MAML1
and MAML2 led to relocalization of endogenous YAP from the
nucleus to the cytoplasm (Fig. 1E and SI Appendix, Fig. S1G). Ad-
ditionally, Western blot analysis revealed that knockdown ofMAML1/
2 dramatically induced YAP in the cytoplasmic fraction, while it re-
duced YAP in the nuclear fraction (SI Appendix, Fig. S1H). Knock-
down of MAML1/2 by short interfering RNA (siRNA) treatment
significantly reduced YAP/TAZ-mediated reporter activity in various
cell lines (Fig. 1F and SI Appendix, Fig. S1 I–K). Importantly, ex-
pression of Notch target genes such as HES1 and NRARP as well as
the YAP/TAZ target genesANKRD1,CTGF, andCYR61 were down-
regulated in MAML1/2-depleted cells, thus validating our knockdown
approach (Fig. 1G). A wound-healing assay demonstrated that YAP
enhanced cell migration, which is consistent with previous reports (38),
while the enhanced cell migration was markedly abolished by de-
pletion of MAML1/2 (Fig. 1H). Taken together, these results suggest
that MAML1/2 interact with YAP/TAZ and promote their nuclear
localization and transcriptional activities.
Nuclear Localization of MAML Is Necessary for the Retention of YAP/
TAZ in the Nucleus.A recent study has shown that YAP contains a
conventional nuclear export signal (NES) (28), but it is currently
unclear if YAP/TAZ also have an NLS. Previous work suggests
that the N-terminal region (1 to 55 amino acids) in Yorkie, a
Drosophila homolog of human YAP, has a potential NLS that
promotes nuclear import of Yorkie via interaction with importin
α1 (39). However, the human homolog of importin α1, KPNA6,
did not display a physical interaction with YAP, nor did it induce
its nuclear translocation in mammalian cells (39). Upon close
inspection, we found that the amino acid sequence of the
N-terminal domain of YAP displayed poor homology with that
of Yorkie. We also noticed that Arg15, a residue of Yorkie that
is critical for binding to importin α1, is not conserved in YAP (SI
Appendix, Fig. S2A). Furthermore, an N-terminal truncated form
of YAP (YAPΔ58) enhanced reporter activity similar to wild-
type YAP, and MAML1-mediated nuclear localization of YAP
was unaffected in YAPΔ58 mutants (SI Appendix, Fig. S2 B and
C). More recently, it has been shown that the C-terminal domain
of TAZ has a nonclassical NLS (30). However, a mutant form of
YAP with a mutation in the conserved sequences (hereafter
referred to as YAP–mpNLS; SI Appendix, Fig. S2D) induced
normal YAP reporter activity. In addition, YAP–mpNLS-
mediated reporter activity as well as nuclear localization of
YAP–mpNLS were further enhanced by the ectopic expression
of MAML1 (SI Appendix, Fig. S2 E and F). Overall, these data
suggest that mammalian YAP may lack a functional NLS, or, at
the very least, the reported NLS sequences are not necessary for
MAML-mediated nuclear localization of YAP.
Because MAML1/2 promote YAP/TAZ nuclear localization,
and YAP does not have a distinct NLS, we hypothesized that the
NLS of MAML, which has not been characterized, is necessary
for YAP nuclear localization. NLS prediction software such as
cNLS mapper, PSORTII, and NucPred predicted the 138- to
142-amino-acid stretch (KKTRR) as a putative NLS for
MAML1 (Fig. 2A). We mutated the putative NLS of MAML1
(KKTRR to AATLL; hereafter referred to as MAML1–mNLS)
and analyzed its subcellular localization in HEK293 cells
(Fig. 2B). Notably, MAML1–mNLS was mainly localized in the
cytoplasm, and it did not induce nuclear localization of YAP
when compared to wild-type MAML1 (Fig. 2B and SI Appendix,
Fig. S2G). Consistently, MAML1–mNLS induced much lower
reporter activity than wild-type MAML1 in HCT116 colon can-
cer cells (Fig. 2C). A wound-healing assay revealed reduced cell
migration upon depletion of MAML1/2, which was markedly
rescued by reintroduction of wild-type MAML1, but not
MAML1–mNLS (Fig. 2D). However, our results do not rule out
the possibility that MAML1/2 may regulate cell migration
through alternative signaling events other than YAP/TAZ.
Based on these observations, we hypothesized that MAML1/2
can affect YAP/TAZ nuclear localization by either promoting its
transport to the nucleus from the cytoplasm or by enhancing its
nuclear retention. Live cell-imaging analysis with HEK293 cells
using doxycycline-inducible mCherry–MAML1 and EGFP–YAP
showed that MAML1 localized to the nucleus earlier than YAP
and that both proteins colocalized in the nucleus only at a later
time point (Fig. 2 E, Upper). However, it is still possible that
GFP–YAP can be phosphorylated by the Hippo pathway, which
may result in slower nuclear translocation of YAP. To address
this possibility, nuclear localization of the Hippo-resistant mu-
tant YAP (YAP-5SA) upon inducible expression of mCherry–
MAML1 was examined (Fig. 2 E, Lower). Consistently, the YAP-
5SA translocated to the nucleus much faster than wild-type YAP
upon MAML1 expression. However, we still noticed that nuclear
localization of MAML1 was observed earlier than YAP, even in
YAP-5SA mutants. While mCherry–MAML1 is strictly present
in the nuclei upon doxycycline treatment, the presence of YAP-
5SA in the cytoplasm seems to disappear and is enriched in the
nucleus upon inducible expression of MAML1. Collectively, our
findings suggest that the NLS in MAML1 is essential for the
nuclear localization of YAP and that this enhanced nuclear lo-
calization is likely caused by nuclear retention. Nonetheless, we
cannot completely exclude the possibility that MAML1/2 facili-
tates the translocation of YAP/TAZ into the nucleus.
The WW Domains of YAP/TAZ and the PPxY Motif of MAML1/2 Are
Required for the Interaction between YAP/TAZ and MAML1/2. It is
well known that the phosphorylation status of YAP–Ser127 de-
termines the nuclear localization of YAP (40) and that YAP is
phosphorylated by LATS1/2 kinase. We tested whether nuclear
localization of YAP induced by the absence of LATS1/2 is
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affected by MAML1/2 depletion. Knockdown of MAML1/2 ef-
ficiently redistributed YAP/TAZ to the cytoplasm in wild-type
HEK293A cells, while in LATS1/2 knockout (KO) cells, YAP/
TAZ was retained in the nucleus (SI Appendix, Fig. S3A). Although
it appears that the cytoplasmic staining was somewhat increased,
quantification of nuclear YAP did not reveal a significant difference.
Despite not observing a significant difference by immunofluores-
cence (IF) upon MAML depletion in LATS1/2 KO cells, we could
see a clear reduction in YAP reporter activity, which is a much more
quantitative and reliable analysis compared to IF (SI Appendix, Fig.
S3B). We believe that excessive nuclear influx of YAP due to its
stabilization via LATS1/2 depletion may override the cytoplasmic
Fig. 3. The WW domains of YAP/TAZ and the PPxY motifs of MAML1/2 are required for the interaction between YAP/TAZ and MAML1/2. (A) YAP-mWW does
not interact with MAML1. (B) Nuclear localization of YAP-mWW is not induced by ectopic expression of Flag-MAML1. (Scale bars, 10 μm.) (C) YAP-
mWW–mediated reporter activity in HEK293T cells is not further enhanced by MAML1. (D) PPxY motifs in MAML1/2 are highly conserved in various spe-
cies. (E) MAML1–PPxA shows reduced interaction with YAP. (F) MAML1–PPxA does not enhance YAP reporter activity in HCT116 cells as much as wild-type
MAML1. (G) The nuclear localization of YAP was not induced by ectopic expression of MAML1–PPxA. (Scale bars, 10 μm.) (H) MAML1–PPxA did not rescue
retarded HEK293 cell migration induced by MAML1/2 depletion. Wound-healing assay and analysis were performed as described in Fig. 2D. In C and F, the
statistical analysis represents average values from a representative experiment performed in triplicate. Error bars represent SDs of triplicate assays. **P < 0.01.
n.s., not significant. Student’s t test was used for statistical analysis. Ctrl, control; WT, wild type.








localization caused by MAML1/2 depletion. This probably explains
why we can only detect a difference with more sensitive methods such
as the YAP reporter assay. These data suggest that the unphos-
phorylated form of YAP can be retained in the nucleus by MAML1.
Recently, we suggested that Nemo-like kinase (NLK) functions as a
counteracting kinase against LATS1/2 by phosphorylating YAP at
Ser-128 (41). We then tested whether the phosphorylation status on
YAP may affect its binding affinity to MAML1/2. Co-IP experiments
with ectopically expressed phospho-mimic forms of YAP (41) and
MAML1 did not show any differences in binding affinities, indicating
that the interaction between MAML1/2 and YAP/TAZ may be
mediated through other domains rather than those phosphorylated
by LATS1/2 or NLK (SI Appendix, Fig. S3C).
As YAP contains WW domains known to be involved in
protein–protein interactions (42), we tested mutant constructs
for interaction with MAML1 (SI Appendix, Fig. S3D). Strikingly,
the MAML1–YAP/TAZ interaction was robustly abolished when
the WW domains were mutated in YAP or deleted in TAZ
(YAP-mWW or TAZΔWW) (Fig. 3A and SI Appendix, Fig. S3E).
Furthermore, nuclear localization and transcriptional activity of
YAP-mWW or TAZΔWW were not induced by MAML1 (Fig. 3 B
and C and SI Appendix, Fig. S3 F–H). To further confirm the im-
portance of the WW domain, we tested whether nuclear localiza-
tion of the Hippo signaling insensitive YAP mutant (YAP-5SA and
YAP-5SA–mWW [mutation as shown SI Appendix, Fig. S3D was
introduced in YAP-5SA]) could be enhanced by ectopic expression
of MAML1. Overexpression of MAML1 was able to dramatically
enhance the nuclear localization of YAP-5SA, while its effects on
YAP-5SA–mWW nuclear localization were minimal (SI Appendix,
Fig. S3I). Consistent with these data, overexpression of MAML1
enhanced YAP reporter activity induced by YAP-5SA, whereas
YAP-5SA–mWW-induced reporter activity was not enhanced by
MAML1 overexpression (SI Appendix, Fig. S3J). These results
support our hypotheses that the WW domain of YAP is necessary
for the interaction with MAML1 and that nuclear localization of
YAP occurs independently of LATS-mediated phosphorylation.
Because the WW domain functions as a protein–protein interaction
module that binds to a PY motif (PPxY, where x is any amino acid)
(43), we attempted to find putative PYmotifs in MAML proteins by
comparative sequence analysis. Interestingly, we found that MAML1
and MAML2, but not MAML3, contain an evolutionarily conserved
PY motif (Fig. 3D). The mutated PY motif (PPxY to PPxA) con-
taining MAML1 (MAML1–PPxA) showed a reduced interaction
with YAP in HEK293T cells and did not increase YAP/TAZ re-
porter activity in HCT116 cells when compared to wild-typeMAML1
(Fig. 3 E and F). Furthermore, MAML1–PPxA did not promote
nuclear localization of YAP, even though MAML1–PPxA nuclear
localization persisted (Fig. 3G and SI Appendix, Fig. S3K). These
results are consistent with our data, demonstrating that MAML1/2,
but not MAML3, promote nuclear localization and enhance YAP/
TAZ reporter activities (Fig. 1D and SI Appendix, Fig. S1 D–F).
Overall, these data suggest that the PPxY motif of MAML1/2 is es-
sential for the interaction with and nuclear localization of YAP/TAZ.
This notion was further confirmed via wound-healing assay, which
showed that the inhibition of cell migration byMAML1/2 knockdown
was completely rescued by reinduction of wild-type MAML1, but not
by MAML1–PPxA (Fig. 3H). However, our results once again do not
rule out the possibility that MAML1/2 may regulate cell migration
through alternative signaling events other than YAP/TAZ. Contrary
to the effect on YAP/TAZ activities, MAML1–PPxA was able to
enhance NICD (Notch Intracellular C-terminal Domain)-mediated
reporter activity to a similar degree as wild-type MAML1, demon-
strating a Notch-independent effect of MAML1–PPxA in the wound-
healing assay shown in Fig. 3H and SI Appendix, Fig. S3L. Collec-
tively, our findings indicate that the interaction between MAML1/2
and YAP/TAZ, which is mediated through the PPxY motif of
MAML and the WW domain of YAP/TAZ, is essential for the nu-
clear localization and transcriptional activity of YAP/TAZ.
MAML1/2 Act as Transcriptional Coactivators by Forming a Trimeric
Complex with YAP/TAZ and TEAD. Since MAML is known to act as
a transcriptional coactivator of several signaling pathways (34),
we examined whether nuclear MAML could act as a coactivator
of YAP/TAZ-mediated transcription. We reasoned that if MAML1/2
are only involved in nuclear retention of YAP/TAZ, MAML1/2
should not enhance the artificial NLS-fused YAP-mediated reporter
activity. Contrary to our expectations, depletion of MAML1/2
exhibited significantly reduced reporter activity, despite the fact that
NLS-fused YAP did indeed localize to the nucleus (Fig. 4A and SI
Appendix, Fig. S4A). Moreover, ectopic expression of MAML1 fur-
ther increased NLS-fused YAP mediated reporter activity, indicating
that MAML1 has additional functions that are independent from
YAP/TAZ nuclear retention (Fig. 4B). It is known that the
C-terminal domain of MAML acts as a transactivation domain
(TAD) to enhance Notch target gene expression via forming a
complex with NICD and the transcription factor CSL (34). In-
terestingly, MAML1ΔTAD, which contains a deletion of the
MAML1 Notch TAD (SI Appendix, Fig. S4B), did not further
enhance NICD as well as YAP/TAZ-mediated reporter activities
(Fig. 4C and SI Appendix, Fig. S4C). These data suggest that
MAML proteins function as coactivators by forming a complex
with TEAD, which mainly acts as a DNA-binding protein for
YAP. IP assay revealed that MAML1 forms a ternary complex
together with YAP and TEAD (Fig. 4D). Knockdown of YAP/TAZ
and analysis of a YAP mutant (Flag–YAP-S94A that cannot bind
TEAD) revealed a reduction in the MAML–TEAD interaction
(Fig. 4E and SI Appendix, Fig. S4D), suggesting that MAML–YAP/
TAZ–TEAD form a trimeric complex. Through chromatin IP (ChIP)
assay, we found that promoter regions of the endogenous YAP/TAZ
target genes, ANKRD1 and CTGF, were occupied by MAML1, while
the nonspecific gene FAT3 displayed no binding (Fig. 4F). Further-
more, ChIP assay with an anti-V5 antibody after transfection with
V5 epitope-tagged MAML1 showed that V5-MAML1 binds to the
promoters of YAP target genes, but not to the promoter of the
nonspecific gene HBB. Importantly, these binding interactions were
significantly reduced by knockdown of TEAD1/3/4 (Fig. 4G). Since
we demonstrated that TEAD4 also promoted the localization of
YAP (Fig. 1A), we tried to distinguish between the roles of MAML1/
2 and TEADs in relation to YAP/TAZ nuclear retention. We ana-
lyzed the effect of TEAD4 on the subcellular localization of YAP/
TAZ in MAML1/2-depleted cells. Interestingly, ectopic expression of
TEAD4 was able to dramatically induce YAP nuclear localization,
even after MAML1/2 depletion (SI Appendix, Fig. S4E). Since
MAML1/2 does not have a DNA binding domain, we believe that
TEADs are required for the localization of MAML1/2 to the pro-
moter region of YAP/TAZ target genes and that the interaction
between YAP/TAZ and TEADs is strengthened by MAML1/2
(Fig. 4 E and G and SI Appendix, Figs. S4D and S7). As MAML1/2
bind NICD and YAP/TAZ via different domains, it is possible that
these proteins form a large complex in the nucleus and regulate both
Hippo and Notch signaling. However, IP data clearly showed that
NICD is not present in the YAP–MAML1/2–TEAD protein com-
plex (SI Appendix, Fig. S4F). Consistently, MAML1 enhanced YAP/
TAZ-dependent reporter activity, while ectopic expression of NICD
had no effect (SI Appendix, Fig. S4G). Consistently, YAP also did not
enhance NICD-mediated reporter activity (SI Appendix, Fig. S4H).
Overall, these results strongly suggest that MAML1/2 form a complex
with YAP and TEAD at the promoter regions of YAP/TAZ target
genes in order to enhance their expression.
Cell-Density-Dependent Regulation of MAML1 and MAML2. Since the
level and nuclear localization of YAP/TAZ are regulated in a
cell-density-dependent manner (6) and MAML1/2 bind to YAP/
TAZ to promote their nuclear localization, we wondered whether
the level of MAML1/2 is also controlled in a cell-density-dependent
manner. At low cell density, MAML1, like YAP, displayed high
nuclear abundance, and this was substantially reduced at higher cell
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densities (Fig. 5 A and B). Interestingly, YAP remained in the
nucleus to some extent in cells where MAML1 was still present,
whereas YAP was predominantly present in the cytoplasm of cells
with low levels of MAML1 (Fig. 5 A and B). Western blot analysis
further confirmed that YAP/TAZ, as well as MAML1/2, were re-
duced in a cell-density-dependent manner in various cell lines
(Fig. 5C and SI Appendix, Fig. S5A). NICD-mediated Notch re-
porter activity as well as YAP reporter activity were gradually de-
creased as cell density increased, further confirming that MAML1/2
levels are reduced at high cell densities (SI Appendix, Fig. S5B).
As both the Hippo pathway and the levels of MAML1/2 are
regulated by cell density, we speculated that MAML1/2 levels
could be down-regulated by Hippo signaling components that
sense and mediate cell-contact inhibition (6, 44). However,
knockdown of the core Hippo components NF2, MST1/2,
LATS1/2, or YAP did not affect the levels of MAML1/2 (SI
Appendix, Fig. S5C). Besides MAML1/2’s roles in nuclear re-
tention and transcriptional activation of YAP, we can imagine
that MAML1/2 may regulate AMPK or LATS1/2 activity by an
unknown mechanism during active Hippo signaling conditions.
We then tested the effect of MAML1/2 depletion on the control
of LATS kinase activity and its upstream effector, AMPK (45).
However, knockdown of MAML1/2 did not affect the activities
of LATS or AMPK, as determined by their phosphorylation
levels (SI Appendix, Fig. S5D). Overall, these results suggest that
MAML1/2 are controlled by cell-density-related mechanisms
that are independent of the Hippo pathway.
To elucidate the molecular mechanisms underlying cell-
density-dependent MAML1/2 down-regulation, we exam-
ined relative messenger RNA (mRNA) expression at various cell
densities. As expected, expression of the YAP/TAZ target genes
ANKRD1 and INHBA was reduced at high cell density (Fig. 5D).
MAML1 mRNA levels were significantly reduced at high cell
density, although the decrease was not as evident as that ob-
served at the protein level. MAML2 mRNA levels were not
significantly altered (Fig. 5D). Together, these data point toward
posttranscriptional regulation of MAML1/2 at high cell densities.
We therefore sought to find specific miRs that can inhibit
translation of MAML1/2 mRNAs, since global activation of miR
biogenesis has been shown to be induced by cell–cell contact
(46–49). Using a reliable prediction program (TargetScanHuman;
http://www.targetscan.org/vert_72/), we identified miR-30c as a
potential candidate for MAML1. We were not able to identify
suitable candidates for MAML2. miR-30c contains a highly con-
served region targeting MAML1 mRNA, and the expression of
miR-30c was greatly increased at high cell density in a similar
manner as miR-15a and miR-29b, both of which have been pos-
itively correlated with cell density (46) (Fig. 5E and SI Appendix,
Fig. 4. MAML1/2 act as transcriptional coactivators by forming a trimeric complex with YAP/TAZ and TEAD. (A) MAML1/2 KO cell pools exhibited reduced
NLS–YAP-mediated reporter activity. (B) NLS–YAP-mediated reporter activity was further enhanced by MAML1 overexpression. (C) MAML1ΔTAD did not
induce YAP reporter activity when compared to wild type. (D) Co-IP assay showed that MAML1 interacted with YAP and TEAD1. (E) Depletion of YAP/TAZ
reduces interaction between MAML1 and TEAD. (F) ChIP assay showed that MAML1 and YAP co-occupies on the promoters of YAP target genes. FAT3 was
used for negative control. (G) ChIP assay showed that TEAD1/3/4 are required for MAML1 to bind the promoters of YAP target genes. HBB was used as a
negative control. The statistical analyses represent average values from a representative experiment performed in triplicate. Error bars represent SDs of
triplicate assays. *P < 0.05; **P < 0.01. n.s., not significant. Student’s t test was used for statistical analysis. Ctrl, control.








Fig. S5E). Consistently, ectopic expression of miR-30c led to a
reduction in MAML1 protein levels as well as YAP-mediated
reporter activities, while miR-15a, which does not have a seed
sequence for targeting MAML1 mRNA, had no effect (Fig. 5 F
andG and SI Appendix, Fig. S5 F andG). The decrease in MAML1
resulting from miR-30c treatment was rescued by the addition of an
inhibitor of miR-30c, which resulted in increased MAML1 protein
levels and YAP reporter activity (Fig. 5 H and I and SI Appendix,
Fig. S5H). The reduced MAML1 level observed at high cell density
was also restored by treatment with the miR-30c inhibitor (Fig. 5J).
In addition, fractionation analysis showed that the levels of nuclear
YAP/TAZ were increased by treatment with the miR-30c inhibitor
(Fig. 5K and SI Appendix, Fig. S5I). Taken together, these results
suggest that MAML1 protein abundance is regulated by both tran-
scriptional and posttranscriptional mechanisms that are directly
influenced by cell density. Thus far, we have focused on the role of the
miR–MAML axis in mediating cell-density-dependent regulation of
YAP/TAZ. We next examined whether the miR–MAML–YAP/TAZ
axis can be regulated by other Hippo signaling activation conditions.
Although less than the decrease observed by cell density, glucose and
serum starvation also reduced the abundance of MAML1/2, whereas
actin–cytoskeleton rearrangement had no effect (SI Appendix, Fig.
Fig. 5. Cell-density-dependent regulation of MAML1 and MAML2 and the involvement of miR-30c in the regulation of MAML1. (A) MAML1 and YAP
colocalize in the nucleus or cytoplasm of HEK293 cells in a cell-density-dependent manner. HD, high cell density; LD, low cell density. (Scale bars, 10 μm.) (B)
Quantification of MAML1 and YAP cellular localization shown in A. (C) Protein levels of MAML1/2 are reduced in HEK293 cells grown in high density. (D) qPCR
assay showed that mRNA levels of MAML1, but not MAML2, were decreased in HEK293A cells grown in high density. (E) The level of miR-30c is increased in
cells grown at high density. miR-15a and miR-29b were used for positive controls. (F, Upper) Ectopic expression of miR-30c mimics reduced MAML1 protein
levels. (F, Lower) ImageJ was used to calculate the relative level of MAML1. (G) Ectopic expression of miR-30c mimics in HEK293 cells reduced YAP-mediated
reporter activity. (H, Upper) Ectopic expression of an inhibitor of miR-30c in HEK293 cells increased MAML1 protein levels. (H, Lower) The relative level of
MAML1 was analyzed by ImageJ. (I, Upper) Ectopic expression of miR-30c inhibitor in HEK293 cells increased YAP-mediated reporter activity. (I, Lower)
Western blotting shows an equal amount of YAP expression. (J, Upper) Ectopic expression of a miR-30c inhibitor in HEK293 cells increased MAML1 protein
level grown in high cell density. (J, Lower) The relative level of MAML1 was analyzed by ImageJ. (K) Ectopic expression of an miR-30c inhibitor in HEK293 cells
increased the MAML1 level as well as nuclear localization of YAP and TAZ. The statistical analyses represents the average values from a representative ex-
periment performed in triplicate. Error bars represent SDs of triplicate assays. *P < 0.05; **P < 0.01. Student’s t test was used for statistical analysis.
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S5 J–L). Consistent with the alteration of MAML1 levels, we found
that miR-30c was induced in glucose or serum depletion, while it was
not affected by actin rearrangement (SI Appendix, Fig. S5 J–L). Based
on these results, we suggest that cell density may be a major physio-
logical factor in regulating miR-30c levels since significantly higher
miR-30c expression was induced by high cell density in comparison
with other physiological conditions.
MAML1/2 Display Oncogenic Properties, and Their Protein Levels Are
Positively Correlated with the Expression of YAP/TAZ Target Genes in
Cancer. Elevated YAP/TAZ activity and nuclear enrichment of
YAP/TAZ have been reported in many types of human cancer
such as colon, lung, breast, and liver cancers (10). Given the role
of MAML1/2 in promoting YAP/TAZ nuclear localization and
activity, we next examined whether MAML1/2 contribute to the
oncogenic function of YAP/TAZ. To this end, we first compared
the relative expression of MAML1/2 and YAP/TAZ in various
colorectal cancer cell lines and found that HCT116 cells express
high levels of MAML1/2 and YAP/TAZ (SI Appendix, Fig. S6A).
HCT116 cells transfected with either YAP or MAML1 alone
exhibited higher growth rates compared to control cells, and
cotransfection of YAP and MAML1 led to a synergistic effect
(Fig. 3 A–C). Importantly, cotransfection of YAP-mWW and
MAML1 did not lead to a synergistic effect on growth rate (SI
Appendix, Fig. S6B). To further examine whether MAML1
overexpression cooperates with activated YAP in transformation/
tumorigenesis, colony-forming (Fig. 6A and SI Appendix, Fig.
S6C), transwell, and invasion assays (Fig. 6B and SI Appendix, Fig.
S6D) were performed. In all assays, we obtained similar results
to the cell-proliferation assay shown in SI Appendix, Fig. S6B.
Moreover, a synergistic effect was observed upon cotransfection
of YAP and MAML1, but not with YAP-mWW and MAML1.
Taken together, these data strongly suggest that MAML1 pro-
motes YAP-mediated tumorigenesis rather than activating other
signaling pathways. To further confirm our hypothesis, we then
performed a xenograft assay using HCT116 cells. Strikingly,
MAML1/2 depletion by short hairpin RNAs dramatically sup-
pressed xenograft tumor growth (Fig. 6 C and D and SI Appendix,
Fig. S6E). Interestingly, immunohistochemistry analysis revealed
not only a robust reduction in protein levels, but it also revealed
nuclear exclusion of YAP/TAZ in tumors from MAML1/2-de-
pleted HCT116 cells (Fig. 6 E and F). It is thus likely that the
in vivo decrease of YAP/TAZ levels may be due to increased
cytoplasmic localization of YAP/TAZ, which ultimately leads to
phosphorylation by LATS1/2 and proteasomal degradation. To
further extend our findings into the pathological condition, we
performed immunohistochemical staining of MAML1/2 and YAP
using a lung-cancer tissue microarray. MAML1 expression was
undetectable in lung tumors, probably due to poor antibody sen-
sitivity or low levels of MAML1 in lung tissue (50, 51). In-
terestingly, while none of normal lung tissues exhibited positive
signals for YAP (0 of 10) and MAML2 (0 of 10), positive ex-
pression of MAML2 and YAP was observed in 26.4% (29 of 110)
and 62.7% (69 of 110) of lung tumors, respectively (SI Appendix,
Fig. S6F). More importantly, a significant positive correlation
between MAML2 and YAP expression was observed in lung
cancer. In fact, 65.7% (23 of 35) of lung-tumor tissues showed
positive MAML2 expression when YAP protein levels were also
high (Fig. 6 G and H and SI Appendix, Fig. S6G), whereas 91.2%
(31 of 34) of lung tumors with negative MAML2 expression
exhibited low YAP levels (Fig. 6 G and H and SI Appendix, Fig.
S6G). Overall, these results suggest that high levels of MAML2
promote YAP-mediated tumorigenesis in a substantial proportion
of human lung tumors.
Next, we referred to TCGA databases, including lung squa-
mous carcinoma and breast and liver cancers, to determine
whether there is a correlation between MAML2 expression and a
YAP/TAZ transcriptional signature. These analyses revealed a
positive correlation between the level of MAML2 and YAP/TAZ
target genes, such as CTGF, CYR61, and AMOTL2, in several
types of human cancers (Fig. 6I and SI Appendix, Fig. S6 H and
I). However, MAML2 and the Notch target genes HEY1, HES1,
and NRARP in human lung cancer were not significantly corre-
lated (SI Appendix, Fig. S6J), suggesting that lung tumors which
have a high level of MAML2 are most likely not induced by
Notch signaling. Consistently, a high level of MAML2 was as-
sociated with worse overall survival in patients with lung squa-
mous carcinoma (Fig. 6J). Thus, elevated MAML2 expression in
human cancers is associated with YAP/TAZ activation and re-
duced survival. Overall, these results not only demonstrate
pathological relevance between MAML expression and YAP/
TAZ activities in tumorigenesis, they also suggest a potential
mechanism underlying YAP/TAZ activation in a variety of
human cancers.
Discussion
Regulating nuclear localization of YAP/TAZ is an essential step
in the Hippo signaling pathway that controls the expression of
genes responsible for maintaining cell proliferation and organ
size. The regulation of cytoplasmic YAP/TAZ localization has
been almost fully elucidated, but the mechanisms underlying
nuclear YAP/TAZ localization are still under intensive in-
vestigation (26–30). The reasons for the presence of totally in-
dependent mechanisms for regulating nuclear localization of
YAP/TAZ are not clear. This may reflect a unique importance of
determining nuclear localization of YAP/TAZ or may be simply
related to differences in cellular context. In this study, we report
that MAML1/2, which are known coactivators of Notch signal-
ing, promote nuclear localization of YAP/TAZ and enhance
YAP/TAZ transcriptional activity (SI Appendix, Fig. S7). We
show that endogenous MAML1/2 interact with YAP/TAZ
through a PPxY motif and WW domain, respectively, and that an
NLS in MAML1/2 is essential for the nuclear localization of
YAP/TAZ. Xenograft experiments, analysis of human lung
cancer tissues, and TCGA data reveal that the levels of MAML2
are strongly correlated with nuclear YAP/TAZ and the expression
of YAP/TAZ target genes. Importantly, two recent independent
whole genome-wide studies identified highly recurrent YAP1–
MAML2 fusions in multiple types of cancers (52, 53). In addition,
Gene Set Enrichment Analysis showed that a YAP1-conserved
transcriptional signature was the most significant hit in YAP1–
MAML2–fusion positive cell lines (52). In both papers, fusions
between YAP1 exons encoding the N-terminal domain of YAP1,
which has a TEAD binding domain, and theMAML2 exons 2 to 5,
which code for the TAD, are the most recurrent. Interestingly, as
we identified the NLS for MAML1 (Fig. 2), NLS prediction
softwares such as cNLS mapper predicted the 188- to 208-amino-acid
stretch, which is encoded by exon2, as a putative NLS for
MAML2. These findings substantiate our results in the clinical
setting and suggest that blocking the interaction between MAML2
and YAP can be a novel therapeutic target for interruption of
cancer progression.
Nuclear localization is highly influenced by protein size. When
a protein’s molecular mass is lower than 40 kDa, it can enter the
nucleus by passive diffusion (54). YAP’s size is around 75 kDa,
so it requires an NLS for nuclear translocation. However, a
classical NLS in the YAP amino acid sequence has not yet been
discovered, and the mechanism for its nuclear translocation is
unknown. Since we found that MAML1/2 interact with YAP/
TAZ, and identified a functional NLS in MAML1, we initially
hypothesized that MAML1/2 could facilitate the translocation of
YAP/TAZ into the nucleus. Although we cannot completely
exclude this hypothesis, the following evidence supports the idea
that MAML1/2 do not promote YAP/TAZ nuclear trans-
location; rather, it enhances its retention in the nucleus by
forming a complex with TEAD. 1) Live cell-imaging data showed








Fig. 6. MAML1/2 display oncogenic activities, and MAML2 protein levels are strongly correlated with the expression of YAP/TAZ target genes in lung cancer
patients. (A) MAML1 enhances colony-forming activity of YAP. (B) Migration and invasion ability of HCT116 cells were enhanced upon cotransfection with
MAML1 and YAP. (Magnification, x200.) (C and D) Knockdown of MAML1/2 in HCT116 cells shows reduced tumor growth in xenograft experiments. (Scale
bar, 1,000 μm [C].) (E and F) MAML1/2-depleted cell-driven tumors exhibit significantly reduced YAP/TAZ levels when compared to control cell driven tumors.
(Scale bars, 100 μm.) (F) Graph shows percentage of positive MAML1, MAML2, and YAP/TAZ-stained cells in control and MAML1/2-depleted cell-driven tumors
displayed in E. (G and H) The tissue microarray analysis of lung cancer patients showed a positive correlation between MAML2 and YAP protein levels. (G)
Histochemical analysis was performed with antibodies indicated on the left. G, Insets show magnification of the small rectangular region. (Scale bars, 20 μm.)
(H) Graphs showing correlations between the levels of MAML2 and YAP (raw data were presented in SI Appendix, Fig. S6 F and G). Neg., negative; pos.,
positive. (I) The mRNA expression datasets of lung squamous carcinoma patients from the TCGA database show a positive correlation between MAML2 and
YAP target genes. The correlation coefficient (r) was calculated by Pearman’s linear correlation. Two-tailed P value was used for analyzing statistical sig-
nificance. (J) Kaplan–Meier plot shows that high expression of MAML2 is associated with poor prognosis of lung cancer patients. Lower 33rd percentile (n =
161) and upper 24th percentile (n = 117) were analyzed. **P < 0.01.
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that MAML1 localizes to the nucleus much earlier than YAP
(Fig. 2E). 2) MAML1 interacted equally well with various forms
of YAP that have differential phosphorylation statuses on
YAP–Ser-127 and Ser-128 (SI Appendix, Fig. S3C). If MAML1/2
can translocate YAP to the nucleus, YAP–S127D and YAP–
S128A should have a lower affinity to MAML1 since they are
mainly localized in the cytoplasm, and this is clearly not the
case (41).
It was shown that nuclear YAP interacts with p72, which is a
regulatory component of the miR processing complex. YAP se-
questers p72, which leads to inhibition of miR biogenesis at low
cell density or in cancer (47). Conversely, in high cell density,
cytoplasmic YAP cannot interact with nuclear p72, and free p72
promotes miR processing and biogenesis (47). We found that the
level of miR-30c, which targets the 3′ untranslated region of
MAML1, is increased and inhibits MAML protein synthesis in
conditions of high cell density. While the expression of MAML1 is
regulated at the transcriptional as well as the posttranscriptional
level via miR-30c, the expression of MAML2 seems to be controlled
only at the posttranscriptional level in HEK293 cells (Fig. 5).
MAML1 is most likely not a target gene of YAP/TAZ, since
knockdown of Hippo signaling components did not change the
levels of MAML1/2 (SI Appendix, Fig. S5C). Further studies are
needed to discover how MAML1 and MAML2 are differentially
regulated at the transcriptional and posttranscriptional levels,
respectively.
Although our biochemical analyses suggest that MAML1 and
MAML2 play similar roles in the promotion of nuclear locali-
zation and transcriptional activation of YAP/TAZ, MAML2
seems to play a dominant role in the tissues of lung cancer pa-
tients. Tissue microarray data show a strong correlation between
MAML2 and YAP levels in lung cancer patients (Fig. 6 G and
H). TCGA data show a strong correlation between the mRNA
levels of MAML2 and YAP target genes in lung cancer (Fig. 6I).
The dominant role of MAML2 might be due to higher expres-
sion of MAML2 than MAML1 in lung tissues, which has been
shown (50, 51).
We show that MAML1/2 not only promote nuclear localiza-
tion of YAP/TAZ, they also enhance YAP/TAZ–TEAD-medi-
ated transcriptional activity via forming a functional complex
(Fig. 4). The components in the trimeric complex seem to help
each other to form nuclear dots, since coexpressed MAML1 and
YAP colocalized in the nuclear dots much faster than MAML1
alone (Fig. 2E). The biological significance of colocalization of
MAML1 and YAP in nuclear dots is unknown, but it is possible
that these dots may contain a specific locus where the trimeric
complex can bind and regulate the expression of target genes.
Overall, our findings suggest a role of MAML1/2 in the reg-
ulation of Hippo signaling by providing mechanistic insight into
the nuclear localization and transcriptional activation of YAP/
TAZ (SI Appendix, Fig. S7). Furthermore, they highlight the
potential of targeting the miR30c–MAML–YAP/TAZ axis as a
novel therapy for the interruption of cancer progression.
Materials and Methods
Cell Culture and Transfection. HEK293T, HEK293, HEK293A, HEK293A–LATS
KO (a gift from Hyun Woo Park, Yonsei University, Seoul, Republic of Korea),
HeLa, Huh7, HT29, Caco2, DLD-1, SW480, and HCT116 cell lines were cul-
tured in Dulbecco’s modified Eagle medium (DMEM; Lonza, catalog no. 12-
604F; or HyClone, catalog no. SH30243.01) supplemented with 10% fetal
bovine serum (Gibco, catalog no. 26140-079) and 1× Antibiotic-Antimyotic
(Gibco, catalog no. 15240-062) at 37 °C in a humidified 5% CO2 incubator.
The 2-deoxyglucose (25 mM for 4 h) was used for glucose starvation. Serum-
depleted DMEM was used for serum starvation. Latrunculin A (0.5 μM for 4
h) was used for F-actin inhibition. To transfect HEK293T cells with plasmids,
calcium–phosphate (55) or polyethylenimine (PEI) methods were used. For
the PEI method, 10 mg/mL PEI (Sigma, catalog no. 408727) was diluted 1/100
in water (Sigma, catalog no. W4502). Opti-MEM (Gibco, catalog no. 31985-
070), plasmids, and PEI were mixed and incubated for 20 min at room
temperature. Culture medium was changed with fresh medium before
treating transfection mixtures. Lipofectamine 2000 (Invitrogen, catalog no.
11668-019), Lipofectamine 3000 (Invitrogen, catalog no. L3000015), or Tur-
bofect (Thermo Scientific, catalog no. R0531) was used for transforming
HEK293, HeLa, or HCT116 according to the manufacturer’s instructions. To
transfect HEK293T with siRNA, the calcium–phosphate method was used,
and other cell lines were transfected by Lipofectamine RNAiMAX (Invi-
trogen, catalog no. 13778150). siRNA sequences are listed in SI Appendix,
Table S1.
Cloning and Plasmids. YAP sequence was amplified by using cDNA from
HEK293T cells and cloned into pCMV4-Flag (Sigma), pEGFP-C1 (Clontech),
and pCS2-HA3 (constructed in our laboratory) expression vectors. Flag-NICD
was also cloned as described above. V5-MAML1, Flag–mWW-YAP, and
rtTA–2SM2 were purchased from Addgene. mCherry–MAML1 and pBI–
mCherry–MAML1 were obtained from Bionics. Flag–MAML1, Flag–MAML2,
and Flag–MAML3 were provided by Lizi Wu, University of Florida, Gaines-
ville, FL. The 6×-NRE-Luc and 8×-GTIIC-Luc were provided by Cheol O. Joe
and Dae-Sik Lim, KAIST, Daejeon, Korea, respectively. Kun-Liang Guan,
University of California San Diego, La Jolla, CA, provided the pRK5–Myc–
TEAD4 construct. Flag- or V5-tagged MAML1 mutant constructs (PPxA or
mNLS) and EGFP- or Flag-tagged YAP mutant constructs (S127A, S127D,
S128A, S128D, mpNLS, 5SA, or 5SA-mWW) were generated by site-directed
mutagenesis (56) using KOD-Plus-Neo DNA polymerase (TOYOBO, catalog
no. KOD-401). To generate guide RNA (gRNA)–MAML1 and gRNA–MAML2,
annealed gRNA sequences which were designed by using the ATUM gRNA
design tool (https://www.atum.bio/eCommerce/cas9/input) were inserted
into BbsI (NEB, catalog no. R0539S)-digested pSpCas9(BB)-2A-Puro (PX459,
Addgene). gRNA sequences are listed in SI Appendix, Table S1.
Detailed descriptions are provided in SI Appendix,Materials and Methods.
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